ChinaBio® Today Articles

Welcome to the ChinaBio® Today store. As a service to our readers, we offer access to individual articles for only $5.00 (USD) each.  Of course, a subscription is only $20/mo, so you may prefer to subscribe.  If so, click on Subscribe in the menu.

Browse


All Products

Viewing 301 - 315 of 5996 products
AnHeart Sells Japanese Rights for ROS1 TKI to Nippon Kayaku for $40 Million Upfront
$5.00
Available
Hengrui Sells PARP1 Inhibitor to Germany’s Merck in $1.7 Billion Deal
$5.00
Available
Henlius Signs $200 Million Deal with Intas for EU/Indian Rights to its Anti-PD-1
$5.00
Available
Angita Closes $46 Million Series B Extension for Musculoskeletal Disease Therapies
$5.00
Available
Kelun-Biotech Releases Positive Data from TROP-2 ADC in Metastatic Breast Cancer
$5.00
Available
LianBio Sells China Rights to Cardiovascular Drug for $350 Million to BMS
$5.00
Available
OrbiMed Raises $751 Million for Asia Healthcare Fund; $3.6 Billion for Two Other Funds
$5.00
Available
Aiolos Raises $245 Million; Partners Hengrui’s Asthma Drug in $1 Billion Deal
$5.00
Available
Sirius Raises $60 Million for Cardiovascular siRNA Portfolio
$5.00
Available
Hansoh Out-Licenses ADC to GSK in $1.6 Billion Deal
$5.00
Available
AnHeart Says ROS1 Inhibitor Effective for NSCLC in Phase II Trial
$5.00
Available
BeiGene Reports anti-PD-1 Effective in Phase III Trial for Gastric Cancers
$5.00
Available
Ascentage Starts China Phase III trial of TKI for Leukemia
$5.00
Available
Skyline Approved to Start China Trials of Gene Therapy for Macular Degeneration
$5.00
Available
Belief BioMed Signs up Takeda to Commercialize Gene Therapy for Hemophilia in China
$5.00
Available